Speakers - Sachs Associates

More documents

Recommendations

Info

<strong>Speakers</strong> Piers Morgan, CFO, uniQure BV Piers joined uniQure’s predecessor company AMT in December 2009 as Chief Financial Officer. He has over ten years experience as CFO with biotechnology companies, including Phytopharm plc, BioAlliance Pharma SA, and Arrow Therapeutics Ltd. Prior to this period, he gained ten years experience in investment banking, working in Mergers & Acquisitions, and Equity Capital Markets with Close Brothers and Ernst & Young Corporate Finance. He qualified as a Chartered Accountant in London with PricewaterhouseCoopers. Remy Luthringer, Venture Partner, Index Ventures Remy joined the Index Ventures life science team as Chief Medical Officer in 2010. After spending some years in clinical psychiatric practice and getting in parallel a master degree in functional explorations and computer engineering, Remy obtained a PhD in Neurosciences and another in Clinical Pharmacology. Prior to joining Index Ventures, Remy was the CEO of one of the most recognized research institute in neurosciences. Thus he was involved in several European grants and research programs focusing on development and validation of biomarkers/ surrogate endpoints. The latter of these can be implemented in drug development programs with the purpose of reducing the attrition rate and failures in the CNS space and also an early readout of the potential of a molecule as early as Phase I/IIa. Remy is the author of about 50 publications, served on advisory boards of biotech as well as pharmaceutical companies and was involved in the development of more than 150 CNS active molecules. Riccardo Braglia, CEO, Helsinn Healthcare S.A Riccardo has a degree in Business Economics with specialization in Business Management. He is HELSINN GROUP’s Chief Executive Officer and Entrepreneur; Managing Director and Member of HELSINN HOLDING’s Board of Directors, Switzerland and Executive Committee for HELSINN GROUP’s strategic management; Managing Director of Helsinn Healthcare, Switzerland; Managing Director of Helsinn Advanced Synthesis, Switzerland; Member of Helsinn Birex Pharmaceuticals’ Board of Directors, Ireland; and Chairman of Helsinn Therapeutics’ Board of Directors, USA. His main role and functions are to focus on fundamental operational strategies such as high level business development, relationships with pharmaceutical industry, financial, political and regulatory institutions, other stakeholders, public relations and communication internal and external to the Group, as well as final control of Helsinn Group’s business trend. Riccardo is a Board Member of Thorne Research, USA; Member of Management Committee of Chamber of Commerce, Industry and Handicraft of Canton Ticino, Switzerland; Board Member of American School in Switzerland; and Chairman of WS Fashion Holding Switzerland. Richard Godfrey, CEO, BerGenBio Richard is an industrial pharmacist; originally trained as a scientist, his career developed through R&D, supply chain, sales & marketing, since 1999 he has served as Managing Director, CEO, and NED in life science companies. He has worked in UK, Germany, Switzerland and USA for Eli Lilly, Catalant, DCC, Reckitt Benckiser and SwissCaps. During his career Mr. Godfrey has led and been involved in the development and life cycle management of broad range of products and technologies, including Zydis, Vegagel, Cyclosporin, Zyprexia, Cialis, Advil and Temgesic. He has successfully grown businesses organically, secured funding and executed substantial merger, acquisition and divestment transactions in UK, Switzerland, Germany and Romania and USA. In 2008 Mr. Godfrey relocated with his family to Bergen Norway and in 2009 led the formation and spin out of BerGenBio from the University of Bergen. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
<strong>Speakers</strong> Richard Goodfellow, CEO, Scancell Richard has over 30 years international experience in the pharmaceutical industry, in Big Pharma and with Biotech companies. During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of Director of Licensing and New Business Development at Scotia Pharmaceuticals, where he was involved with the company’s flotation on the London Stock Exchange and successfully negotiated numerous deals. In addition to co-founding Scancell’s ImmunoBody cancer vaccine business, Dr Goodfellow was also a co-founder of Paradigm Therapeutics, a Cambridge based functional genomics company and was a former Director of Enact Pharma plc. Robert Burns, CEO, 4-Antibody Robert is CEO at 4-Antibody and is an experienced biotech business leader previously at Affitech A/S and Celldex Therapeutics Inc., both antibody discovery and development companies. Dr Burns joined 4-Antibody following the successful repositioning and refinancing of Copenhagen listed and Oslo-located Affitech A/S (AFFY, NASDAQ OMX). Prior to his time at Affitech, he was CEO at Celldex Therapeutics Inc. (CLDX, NASDAQ) during the critical period of Celldex’s emergence from Medarex through to its eventual reverse merger into NASDAQ-listed Avant Immunotherapeutics. Before his role at Celldex, Dr Burns was at the Ludwig Institute for Cancer Research in New York, where he played leadership roles in the spin-out of several successful companies including Piramed in the UK. Prior to that he was Commercial Director at both Oxford Glycosciences, UK and British Biotech, UK; and previously AbT, Cambridge Mass.; and CIBA-Corning Diagnostics. Dr Burns is also non-executive Chairman of Haemostatix, an early stage UK company specialising in haemostasis blood clotting products and also serves on the board of Oncos Therapeutics Oy, a Finnish developer of novel cancer therapies based on next generation oncolytic viruses. Rolf Guenther, CEO, Bicycle Therapeutics Rolf has over 25 years of pharmaceutical industry experience with an extensive background in drug development, biologics and speciality pharmaceuticals. Since 2004 he has served as CEO and COO of Affimed, a monoclonal recombinant antibody company, and has successfully developed its clinical product portfolio in oncology. He previously held the position of VP and General Manager of the Critical Care business unit of Aventis Behring, which he joined as VP Global Clinical Research in 1996, and was responsible for successful drug approvals in the US and Europe. Dr. Günther is a trained physician in critical care medicine. He received his MD and his PhD in Physical Chemistry from the University of Mainz, Germany. He completed an Executive Development Program at the University of Pennsylvania’s Wharton School of Business. Rolf Witte, CEO, PSites Pharma GmbH Rolf has over 25 years experience in finance and law and has consulted many companies on financial and legal matters. Dr. Witte has a thorough knowledge of the public funding in Germany and has been successful in raising capital for a number of biotech companies. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19: Speakers Paul Higham, Managing Dire
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72:
CONTACTS Aaron Powers President Dav
Page 73 and 74:
CONTACTS General and Media Contact
Page 75 and 76:
CONTACTS Martin Welschof Chief Exec
Page 77 and 78:
CONTACTS Carlos Buesa Chief Executi
Page 79 and 80:
CONTACTS Nick McCooke Chief Executi
Page 81 and 82:
CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84:
CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86:
CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?